Cognition Therapeutics Q3 net loss $9.9M; CT1812 slows decline 95% in Alzheimer's sub-group

COGNITION THERAPEUTICS INC

2024-Q3 EPS reported -$0.69

Net loss $9.9M ($0.25/share) vs $6.7M ($0.22/share) in Q3 2023; cash $22M plus $53.6M NIA grants.
CT1812 showed 95% slowing of cognitive decline (ADAS-Cog11) in Alzheimer's patients with low p-tau217 at CTAD.
On track to report Phase 2 SHIMMER topline results in dementia with Lewy bodies by end of 2024.
Plans to request end-of-Phase 2 FDA meeting for CT1812 Alzheimer's program.
Cash runway into Q2 2025; R&D expense $11.4M, G&A $3.1M both flat YoY.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.